Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,663 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.
Cho EJ, Kim MH, Kim YH, Chang K, Choi DJ, Kang WC, Shin J, Kim SH, Lee N, Son JW, Doh JH, Kim WS, Hong SJ, Rhee MY, Ahn Y, Lim SW, Hong SP, Choi SY, Hyon MS, Hwang JY, Kwon K, Cha KS, Ihm SH, Lee JH, Yoo BS, Kim HS. Cho EJ, et al. Among authors: kwon k. J Clin Hypertens (Greenwich). 2023 Sep;25(9):817-827. doi: 10.1111/jch.14707. Epub 2023 Aug 23. J Clin Hypertens (Greenwich). 2023. PMID: 37614053 Free PMC article. Clinical Trial.
A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy.
Jeon ES, Lim SW, Kim SY, Yang HM, Kim MH, Rhee MY, Han SH, Shin J, Kim KI, Jeong JO, Sung KC, Hong GR, Kim HS, Kwon K, Kang TS, Lee HY, Han SE. Jeon ES, et al. Among authors: kwon k. Clin Hypertens. 2022 Dec 1;28(1):40. doi: 10.1186/s40885-022-00223-4. Clin Hypertens. 2022. PMID: 36451242 Free PMC article.
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension.
Sung KC, Hong SJ, Rhee MY, Jeong MH, Kim DH, Lim SW, Park K, Lee JB, Kim SY, Cho JM, Cho GY, Heo JH, Kim SH, Lee HY, Kim W, Cho DK, Park S, Shin J, Pyun WB, Kwon K, Rha SW, Jung JA. Sung KC, et al. Among authors: kwon k. J Clin Hypertens (Greenwich). 2023 May;25(5):429-439. doi: 10.1111/jch.14656. Epub 2023 Apr 24. J Clin Hypertens (Greenwich). 2023. PMID: 37095689 Free PMC article. Clinical Trial.
A case of amiodarone-associated pulmonary toxicity.
Kwon KH, Jeong SW, Uh S, Kim YH, Jin SY, Park JS, Kang CH, Park CS. Kwon KH, et al. Korean J Intern Med. 1995 Jul;10(2):155-9. doi: 10.3904/kjim.1995.10.2.155. Korean J Intern Med. 1995. PMID: 7495776 Free PMC article.
Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry.
Kim JS, Lee BH, Ko YG, Choi D, Jang Y, Min PK, Yoon YW, Hong BK, Kwon HM, Ahn MS, Lee SH, Yoon JH, Lee BK, Kim BO, Kim BK, Oh SJ, Jeon DW, Yang JY, Cho JR, Jung JH, Ryu SK; Korean Multicenter Angioplasty Team (KOMATE) Investigators. Kim JS, et al. Catheter Cardiovasc Interv. 2008 Nov 1;72(5):601-7. doi: 10.1002/ccd.21700. Catheter Cardiovasc Interv. 2008. PMID: 18942123
A prospective randomized controlled trial to determine the safety and efficacy of extracorporeal shock waves therapy for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Song S, Woo J, Kim H, Lee JW, Lim W, Moon BI, Kwon K. Song S, et al. Among authors: kwon k. Front Cardiovasc Med. 2024 Feb 7;11:1324203. doi: 10.3389/fcvm.2024.1324203. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38385137 Free PMC article.
2,663 results